



PTO/SB/088 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/822,496
		Filing Date	04/12/2004
		First Named Inventor	LEMANSKI et al.
		Art Unit	1653
		Examiner Name	
Sheet 1	of 2	Attorney Docket Number	6818-70

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
M.T.		DAVIS et al., "Induction of myofibrillogenesis in cardiac lethal mutant axolotl hearts rescued by RNA derived from normal endoderm," Development 99:145-154, 1987.	
		DRAGHIA-AKLI, "Enhanced growth by ectopic expression of growth hormone releasing hormone using an injectable myogenic vector," Nat Biotechnol. 15:1285-9, 1997.	
		FRANSEN et al., "Myocardial cell relationships during morphogenesis in normal and cardiac lethal mutant axolotls, Ambystoma mexicanum," Amer J Anat 183:245-257, 1998.	
		LEMANSKI, L. "Role of Tropomyosin in Actin Filament Formation in Embryonic Salamander Heart Cells," J Cell Biol 82:227-238, 1979.	
		LEMANSKI et al., "Normal Anterior Endoderm Corrects the Heart Defect in Cardiac Mutant Salamanders (Ambystoma mexicanum)," Science 204:860-862, 1979.	
		LEMANSKI et al., The Cardiac Mutant Gene c in Axolotls: Cellular, Developmental and Molecular Studies," Cell Molec Biol Res 41: 293-305, 1995.	
		LEMANSKI et al., Molecular biology of heart development in the Mexican axolotl, Ambystoma mexicanum," J Tsitologiya (Cytology) 39:918-927, 1997.	
		LEMANSKI et al., "Cellular, Molecular, and Developmental Studies on Heart Development in Normal and Cardiac Mutant Axolotls, Ambystoma Mexicanum," Chapter 12.	
		SMITH et al., "Heart induction in wild-type and cardiac mutant axolotls (Ambystoma mexicanum)," J Exp Zool 254:48-54, 1990.	
		LEMANSKI et al., "A specific synthetic RNA promotes cardiac myofibrillogenesis in the Mexican axolotl," Biochem Biophys Res Commun 229:974-81, 1996.	

Examiner Signature	<i>M. Tey</i>	Date Considered	07.18.05
--------------------	---------------	-----------------	----------

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/822,496
Filing Date	04/12/2004
First Named Inventor	LEMANSKI et al.
Art Unit	1653
Examiner Name	
Attorney Docket Number	6818-70

Sheet

2

of

2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
M.T.		LEMANSKI et al., "Creation of chimeric mutant axolotls: a model to study early embryonic heart development in Mexican axolotls," Anat Embryol 203:335-342, 2001.	
		PESTOVA et al. "Molecular mechanisms of translation initiation in eukaryotes," Proc Natl Acad Sci 98:7029-7036, 2001.	
		SANBE et al., "Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter," Circ Res. 92:609-16, 2003.	
		SEPULVEDA et al., "Combinatorial expression of GATA4, Nkx2-5, and serum response factor directs early cardiac gene activity," J Biol Chem. 277:25775-82, 2002.	
		ZACKSON et al., "Cranial neural crest cells exhibit directed migration on the pronephric duct pathway: further evidence for an in vivo adhesion gradient," Dev Biol 117:342-353, 1986.	
		ZAJDEL et al., "Alteration of cardiac myofibrillogenesis by liposome-mediated delivery of exogenous proteins and nucleic acids into whole embryonic hearts," Anat Embryol 201:217-228, 1999.	

Examiner
Signature

M. Taylor

Date


Considered

07.18.05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/822,496
		Filing Date	04/12/2004
		First Named Inventor	LEMANSKI
		Art Unit	1653
		Examiner Name	TSAY, MARSHA M.
Sheet 1	of 1	Attorney Docket Number	6818-70

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
M.T.		ZHANG et al., Cloning of a Myofibril Inducing RNA (MIR) that Promotes Myofibrillogenesis, FASEB J., April 2004, vol. 18, no. 4-5, pp. Abst. 4942	
J		CHEN et al., Genetics of heart Development, Trends in Genetics, Sept. 2000, vol. 16, no. 9, pp. 383-388	
↓		HATCHER et al., Atrial Form and Function: Lessons from Human Molecular Genetics, Trends in Cardiovascular Medicine, 2000, vol. 10, no. 3, pp. 93-101	

Examiner Signature		Date Considered	07.18.05
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.